Methylphenidate Stada Arzneimittel Ag

Methylphenidate Hydrochloride, the active ingredient in Methylphenidate Stada Arzneimittel Ag, is a central nervous system stimulant presented as a tablet for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy in children, adolescents, and adults.

GNH USA supplies Methylphenidate Stada Arzneimittel Ag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Methylphenidate Hydrochloride is used in central nervous system stimulant therapy for neurodevelopmental and sleep‑wake disorders. - Attention deficit hyperactivity disorder (ADHD): Improves concentration, reduces hyperactivity and impulsivity in children, adolescents and adults. - Narcolepsy: Decreases excessive daytime sleepiness and improves wakefulness.

Methylphenidate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Insomnia: Difficulty falling or staying asleep. - Decreased appetite: Reduced hunger leading to weight loss. - Headache: Mild to moderate head pain. - Nausea: Stomach upset or feeling sick. - Increased heart rate: Noticeable tachycardia. - Stomach pain: Discomfort or cramps in the abdomen.

Serious or Rare Side Effects: - Cardiovascular events: Hypertension, arrhythmia, or chest pain. - Psychosis: Hallucinations or delusional thinking. - Severe allergic reactions: Rash, swelling, or anaphylaxis. - Priapism: Prolonged erection requiring medical attention. - Growth suppression: Reduced height or weight gain in children. - Seizures: Convulsive episodes in susceptible individuals.

Before prescribing methylphenidate, clinicians should consider several safety precautions. - Cardiovascular assessment: Evaluate blood pressure and heart rate, and review cardiac history before initiation. - Psychiatric screening: Monitor for emergence of anxiety, agitation, or psychotic symptoms, especially in patients with pre‑existing disorders. - Growth monitoring: Track height and weight in children regularly during therapy. - Substance abuse risk: Assess for history of substance misuse, as methylphenidate has potential for dependence. - Store at ambient temperature: Keep tablets below 25 °C in the original container, protected from moisture and light.

Methylphenidate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): Concurrent use may cause hypertensive crisis or serotonin syndrome. - Tricyclic antidepressants: May increase risk of cardiovascular side effects. - Antihypertensive agents: May reduce the blood‑pressure‑lowering effect.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): May enhance serotonergic activity, requiring observation for serotonin syndrome. - Anticonvulsants (e.g., carbamazepine): May decrease methylphenidate plasma levels, reducing therapeutic effect. - Proton pump inhibitors: May modestly increase methylphenidate exposure.